Salute e Benessere

Great Ormond Street Hospital Delegation Participates in International Conjoined…

On the first day of the conference, Mr. Simon Blackburn, Consultant Neonatal and Paediatric Surgeon at GOSH, will present "Ethical aspects of conjoined twins separation". Dr. Felice D'Arco, Consultant Pediatric Neuroradiologist at GOSH, will present "Multiparametric Imaging for Presurgical Planning of Craniopagus Twins," sharing insights into cutting-edge imaging techniques crucial for complex surgical procedures. Professor Paolo De Coppi, Consultant Paediatric Surgeon at…

Zentiva secures approx. 85.27% of APONTIS PHARMA AG voting rights in the context…

Settlement of the offer is still subject to foreign direct investment control clearance in Germany. Settlement is expected to occur in December 2024 or in Q1 2025. Settlement of the offer is still subject to foreign direct investment control clearance inGermany. Settlement is expected to occur inDecember 2024or in Q1 2025. About Zentiva Zentiva is a Pan-European Platform developing, manufacturing and providing high-quality and affordable medicines to more than 100 million people...

Monument Therapeutics Launches First Clinical Study of MT1988, a Novel Treatment…

Preclinical studies of MT1988 have demonstrated promising results, highlighting its potential to improve cognitive deficits associated with schizophrenia. This Phase I placebo-controlled trial is designed to evaluate the safety, tolerability and pharmacokinetics of MT1988 in healthy adults over a 14-day dosing period, with initial results expected in Q1 2025. Preclinical studies of MT1988 have demonstrated promising results, highlighting its potential to improve cognitive deficits associated...

Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast…

ORSERDU is the first and only oral estrogen receptor antagonist (SERD) approved to target ESR1-mutated tumors, which occur in up to 50% of ER+, HER2- advanced or mBC tumors, as a result of prior exposure to endocrine therapy (ET) in the metastatic setting. Since its approval by the U.S. Food & Drug Administration (FDA) in January 2023, sufficient time has passed to be able to characterize the real-world use of ORSERDU in the current mBC treatment landscape. ORSERDU is the first and only…

Phenix Salon Suites Opens Fifth United Kingdom Location in Derby

This new location in Derby signifies continued growth and ongoing success abroad for the brand. Having recently surpassed 400 locations, Phenix is continuing to dominate the salon suite industry on a worldwide scale, anticipating 2 more international openings by the midway point of 2025. The brand's impressive expansion is a testament to the demand from Lifestyle Professionals globally who are seeking independent suites to operate their own business out of, allowing Phenix locations across the…

Philips and AWS expand strategic collaboration to advance HealthSuite cloud…

Cloud-enabled integrated diagnostics portfolio aims to unify workflows, improve access to critical insights, and drive better outcomes for patients Amsterdam, the Netherlands –Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the expansion of its strategic collaboration with Amazon Web Services (AWS) to offer Philips' integrated diagnostics portfolio in the cloud, including radiology, digital pathology, cardiology [1], and AI advanced...

Roquette Successfully Completes Inaugural EUR 1.2 billion Bond Offering to…

Roquette Successfully Completes Inaugural EUR 1.2 billion Bond Offeringto Support its Transformative Acquisition of IFF Pharma SolutionsLille, 26 thNovember 2024 –Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, successfully completed itsinauguralbond offering with adual tranchefor a total of EUR 1.2bn. Both tranches are admitted to trading on Euronext Paris.The bond offering was met with...

ONWARD Medical Provides Q3 2024 Update and Year-to-Date Highlights

Raised EUR 50 million in new capital with cornerstone investment from Ottobock, now the Company's top investorSigned exclusive license with CEA to develop and commercialize WIMAGINE Brain-Computer Interface (BCI) as part of the Company's investigational ARC-BCI System Rob ten Hoedt, former Medtronic President and Executive Committee member, joined Board of Directors as incoming Chairman EINDHOVEN, the Netherlands, Nov.26, 2024(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext:...

Roche enters into a definitive agreement to acquire Poseida Therapeutics…

Acquisition supports Roche's Pharma Strategy and allows for a range of potentially first and best-in-class therapies across oncology, immunology, and neurology, uniquely positioning Roche in the new field of donor-derived off-the-shelf cell therapiesRoche to acquire Poseida Therapeutics for US $9.00 per share in cash at closing, representing a total equity value of approximately US $1.0 billionStockholders would also receive a non-tradeable contingent value right (CVR) for up to an...

Press Release: Transparency Notification from Shareholders

Transparency Notification from ShareholdersGhent, Belgium – 26 November 2024 – Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification in relation to the entities listed below, notifying the number of voting rights attached to the shares mentioned next to their name in the table below. Reason for...

Roche reports update on Phase III SKYSCRAPER-01 study results

SKYSCRAPER-01 is a global phase III, randomised, double-blind study evaluating tiragolumab plus Tecentriq compared to Tecentriq alone in 534 patients with PD-L1-high previously untreated, locally advanced unresectable or metastatic NSCLC. Patients were randomised 1:1 to receive either tiragolumab plus Tecentriq or placebo plus Tecentriq, until disease progression, loss of clinical benefit, or unacceptable toxicity. The study did not reach the primary endpoint of overall survival at the final...

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

thAnnual Evercore ISI HealthCONx Conference on Thursday, December 5, 2024. The presentation will begin at 8:20 A.M. Eastern Time.To access a live webcast of the presentation, visit Teva's Investor Relations website athttps://ir.tevapharm.com/Events-and-Presentations.An archived version of the webcast will be available within 24 hours after the end of the live discussion. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader,...

Major Depressive Disorder Market to Register Immense Growth by 2034 Owing to a…

As per DelveInsight analysis, the total diagnosed prevalent cases of MDD in the 7MM were found to be approximately 44 million cases in 2023, which is expected to increase during the forecast period (2024–2034). Among the severity-specific diagnosed prevalent cases of MDD, the highest prevalence was observed in moderate cases accounting for approximately 17 million cases in the 7MM in 2023 followed by severe cases and mild cases. As per DelveInsight analysis, the total diagnosed prevalent…

Alkermes to Participate in Upcoming Investor Conferences

Piper Sandler 36th Annual Healthcare ConferenceDate/Time: Wednesday, Dec. 4, 2024 at 4:00 p.m. ET (9:00 p.m. GMT) Piper Sandler36 thAnnual Healthcare Conference Date/Time: Wednesday, Dec. 4, 2024 at4:00 p.m. ET( 9:00 p.m. GMT ) The live webcasts may be accessed under the Investors tab onwww.alkermes.comand will be archived for 14 days. About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of...

Genmab to Present at Citi's Global Healthcare Conference

Media ReleaseCOPENHAGEN, Denmark; November 25, 2024Genmab A/S (Nasdaq:GMAB) announced today that its Chief Financial Officer Anthony Pagano will take part in a fireside chat at Citi's 2024 Global Healthcare Conference on December3 , 2024 at 8:30 PMCET/2:30PM EST. A webcast of the event will be available on Genmab's website athttps://ir.genmab.com/events-presentations. About Genmab Genmab is an international...

International Conference on Conjoined Twins in Riyadh Closes with Call to…

Among other items, the conference concluded with a call for the establishment of a dedicated international fund to support conjoined twins, as well as more focused research on rare diseases. Among other items, the conference concluded with a call for the establishment of a dedicated international fund to support conjoined twins, as well as more focused research on rare diseases. Dozens of New Humanitarian Projects Announced Proactive steps announced at the conference include the...

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 25 November 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.Under…

HFO-1234yf Market Analysis 2024: Key Drivers, Segments, and Future Growth Trends…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-3D2730/Covid_19_Impact_on_Global_HFO_1234yf_Market Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-3D2730/Covid_19_Impact_on_Global_HFO_1234yf_Market Major Factors Driving the Growth of HFO-1234yf Market The HFO-1234yf market is expanding rapidly, driven by its adoption in automotive, refrigeration, and personal cooling applications. Key growth factors include stringent...

Bioresorbable Polymers Market worth $867.2 million by 2029 - Exclusive Report by…

140 – Tables 140 – Tables 30 – Figures 300 – Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=235258717 The drug delivery segment is the rapidly growing segment for bioresorbable polymers market. The growth is driven by the high demand of oral capsules. Such polymers have long been employed in the design of implantable matrices for effective drug delivery, especially after encapsulation; nontoxicity associated with such absorption makes...

FutureCeuticals, Inc. and Global Calcium Pvt., Ltd. Announce Strategic…

"We are excited to partner with Global Calcium, extending the reach of our innovative ingredient solutions," said J. Randal Wexler, Vice President and Head of Research & Development at FutureCeuticals. "Their world-class manufacturing capabilities align with our high standards, and this opens doors to some of the world's fastest-growing markets. The decision to utilize their capabilities to help us globalize our industry-leading and innovative joint and bone mineral complex…

Philips and icometrix advance precision diagnosis in neurology with innovative…

November 25, 2024icometrix' FDA-cleared quantitative brain solution for neurological conditions including Alzheimer's and multiple sclerosis is seamlessly integrated into Philips next generation BlueSeal MR scanners, and will be deployed in its comprehensive informatics platform Amsterdam, the Netherlands and Leuven, Belgium –Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, and computer-aided diagnostics companyicometrix(Leuven, Belgium) have teamed...

Rznomics announces to secure the Expanded Access Program for patients with…

GBM is known as the most malignant tumor in Central Nervous system with high mortality rate but lacks effective therapies. TERT promoter mutations, which are associated with TERT upregulation, are found in up to 80% of glioblastoma (GBM) patients. This increased TERT expression is strongly linked to a poor prognosis, reflecting the aggressive nature of the disease. RZ-001, the RNA replacement enzyme-based cancer gene therapy, targets and cleaves hTERT mRNA and replaces the mRNA with the…

Reju and Nouvelles Fibres Textiles Collaborate on Textile Waste Circular…

Reju is developing the infrastructure to take textile waste and regenerate it at scale, starting with polyester. The end product – Reju Polyester™ – is expected to have a 50% lower carbon footprint than virgin polyester and can be regenerated infinitely. Reju's first demonstration plant – Regeneration Hub Zero – is now operational in Frankfurt, Germany, and will come on line to enable the production of Reju PET in 2025. Reju is developing the infrastructure to take textile waste and…

Zero Candida Announces Full Transaction and Being Trading November 25th on the…

Zero Candida is working on creating a technology to enable the hybrid medicine services to be provided by gynecologists to populations that until now received no treatment at all, including, among others, in the developing countries. The ZCT device is Collect and transmits treatment data to the attending physician in real time, for assessment, treatment personalization and monitoring. Seamless data transfer through Wi-fi chip and VoIP, allows for the convenience of remote care and treatment…

Altri Comunicati